EQT seals $9.6bn sale of Covid vaccine DNA supplier Aldevron, less than two years after buyout


Private equity major EQT has agreed a $9.6bn sale of vaccine DNA and mRNA supplier Aldevron to Danaher Corp, just two years after buying into the business.

Aldevron has seen its profile grow amid the coronavirus crisis through its important role supplying plasmid DNA used to manufacture mRNA vaccines.

EQT agreed to buy a majority stake in TA Associates-backed Aldevron in August 2019. The sale marks one of the firm’s largest US transactions to date.

Eric Liu, partner and global co-head of healthcare at EQT, said, “Aldevron is integral to the development and supply of new types of therapies that address previously uncurable medical conditions.

“We are proud to have supported Aldevron and its mission to deliver the highest quality products that help improve patient lives across the world.”

Morgan Stanley & Co acted as exclusive financial advisor to Aldevron, and Simpson Thacher & Bartlett provided legal counsel.

Copyright © 2021 AltAssets

Get the latest PE News & Research delivered to your inbox every morning